Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2020-07-01 Share Issue/Capital Cha…
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d’actions composant le capital social au 30 juin 2020
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2020" (Information relative to the total number of voting rights and shares comprising the share capital as of June 30, 2020). It explicitly details the total number of voting rights (real and theoretical) and the total number of shares outstanding as of a specific date. This type of mandatory disclosure, focusing on the structure of the share capital and voting rights, aligns best with announcements related to capital structure changes or major shareholding notifications. Since it is a specific announcement about the current share count and voting rights, it is most closely related to 'Share Issue/Capital Change' (SHA) or 'Major Shareholding Notification' (MRQ). Given the context of detailing the total capital structure following recent issuances (mentioned in footnote 3), SHA is a strong fit, but MRQ specifically covers changes in significant ownership levels, which often accompanies capital structure updates. However, the content is a direct statement of the total capital structure, which is a fundamental aspect of capital changes. Let's re-evaluate the definitions. SHA is 'Announcement regarding new share issues, stock splits, or other capital changes.' This document reports the *result* of capital changes. MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds).' This document does not report changes by specific shareholders crossing thresholds, but rather the aggregate total. Since the document reports the total number of shares and voting rights, which is a key component of capital structure reporting, SHA is the most appropriate fit among the specific options, as it reflects the current state of the capital base following any recent activity. If a more specific 'Total Capital Disclosure' existed, it would be used, but SHA covers the underlying changes that lead to this report.
2020-07-01 French
Pixium Vision selected to participate in the Next French Healthcare program organized by Business France and BPI France, bolstering presence in the US
Regulatory Filings Classification · 100% confidence The document is a press release dated June 19, 2020, announcing that Pixium Vision was selected for the 'Next French Healthcare' program, which involves a US investor roadshow. It discusses clinical trial progress (Prima System, AMD), regulatory filings preparation (PRIMAvera study), and includes quotes from the CEO and contact information. This type of announcement, focusing on business development, investor relations, and clinical milestones outside of mandated periodic financial reporting (like 10-K or IR), is best classified as a general regulatory announcement or news release. Since it is not a formal financial report, a transcript, a director's dealing, or a specific capital event, the most appropriate general category is Regulatory Filings (RNS), as it is a public disclosure of material, non-financial business information.
2020-06-19 English
Pixium Vision annonce l’activation réussie chez le premier patient de l’étude de faisabilité américaine du Système Prima équipé de la nouvelle génération de lunettes
Regulatory Filings Classification · 100% confidence The document is a press release from Pixium Vision announcing a major clinical milestone: the successful activation of their Prima System in the first US patient for dry Age-related Macular Degeneration (AMD). It details clinical progress, mentions future study plans (PRIMAvera), and provides contact information for investors and media. This type of announcement, focusing on operational and clinical progress rather than comprehensive financial results (like a 10-K or IR) or a formal vote result, is best classified as a general announcement. Since it is a news release about company progress and not a specific regulatory filing like a Director's Dealing or a Dividend Notice, and it doesn't fit the definition of an Earnings Release (ER) which focuses on financial figures, the most appropriate category is Regulatory Filings (RNS) as a general regulatory/corporate announcement, or potentially Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a formal press release. Given the options, RNS serves as the best general announcement/press release category for non-standard filings. The length (5165 chars) is substantial enough that it is not merely an RPA announcing a report, but the report itself (a press release).
2020-03-04 French
Pixium Vision announces Prima System successful activation in first patient in US feasibility study with the new generation of glasses
Regulatory Filings Classification · 100% confidence The document is a press release dated March 04, 2020, announcing a specific operational milestone: the successful activation of the Prima System in the first US patient for a feasibility study related to dry Age-related Macular Degeneration (AMD). It contains key highlights, quotes from management (CEO and Professor Sahel), and contact information. It is not a full annual report (10-K), a comprehensive interim report (IR), or a transcript (CT). It is an announcement of clinical progress and operational updates, which fits best under the general category of a regulatory/corporate announcement. Since it is not a specific announcement like a dividend (DIV), management change (MANG), or financing (CAP), and it is not a formal report itself, it falls under the general 'Regulatory Filings' (RNS) category as a significant corporate update that is not covered by a more specific code. The length (4646 chars) is substantial enough to be a standalone announcement, not just a brief notice of publication (RPA).
2020-03-04 English
Information on total number of voting rights and shares composing the share capital as at February 29th, 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces the 'Information on total number of voting rights and shares composing the share capital as at February 29th, 2020'. This type of filing, which details the current structure of the share capital and voting rights, is most closely related to changes in the capital structure or official shareholder information. Reviewing the definitions, 'Share Issue/Capital Change' (SHA) covers announcements regarding new share issues or capital changes. The content details the total number of shares and voting rights, referencing recent share conversions and financing activities that directly impact the capital structure. While it is not a formal 'Share Issue' announcement, it is a mandatory disclosure regarding the resulting capital structure, making SHA the most appropriate fit among the specific options, as it directly relates to the composition of the share capital.
2020-03-02 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement dated March 2, 2020, titled "Information relative au nombre total de droits de vote et d'actions composant le capital social au 29 février 2020" (Information relative to the total number of voting rights and shares comprising the share capital as of February 29, 2020). It explicitly details the total number of voting rights (real and theoretical) and the total number of shares outstanding as of a specific date. This type of mandatory disclosure regarding the total share count and voting power is typically classified under Share Issue/Capital Change (SHA) or sometimes as a general regulatory filing. Given the specific focus on the capital structure (total shares and voting rights), SHA is the most appropriate fit, as it relates directly to the capital base, even though it's a periodic update rather than a new issuance announcement. It is not a dividend notice (DIV), a major shareholding change (MRQ), or a general financing update (CAP), but a statement of the current capital structure.
2020-03-02 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.